Everest Medicines Launch VELSIPITY® in the Guangdong-Hong Kong-Macau Greater Bay Area

Asian Aussie Business | Shanghai, China | Everest Medicines is pleased to announce the launch of VELSIPITY® in the Guangdong-Hong Kong-Macau Greater Bay Area, providing a new treatment option for patients with moderately to severely active ulcerative colitis.

Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company dedicated to the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, has received official approval for VELSIPITY® for patients with ulcerative colitis by the Guangdong Provincial Medical Products Administration. The medication will first be available at Foshan Fosun Chancheng Hospital and the First Affiliated Hospital of Sun Yat-sen University in the Greater Bay Area, in line with the “Hong Kong and Macau Medicine and Equipment Connect” policy. VELSIPITY® will subsequently be introduced in other qualified hospitals under this policy, marking the third commercialized product of Everest Medicines.

VELSIPITY® is an advanced therapy approved for the treatment of moderately to severely active ulcerative colitis in patients aged 16 and above. With the number of UC patients in China expected to double by 2030, there is a significant need for innovative therapies. Everest Medicines is committed to providing patients with access to advanced treatments and plans to submit VELSIPITY® for new drug application in mainland China by the end of the year.

Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, stated, “The launch of VELSIPITY® in the Greater Bay Area will improve access to advanced therapy for patients with ulcerative colitis. We are dedicated to delivering innovative therapies to patients efficiently and will continue to explore ways to enhance accessibility. Our goal is to benefit more patients by expanding the availability of VELSIPITY®.”

VELSIPITY® was developed by Arena Pharmaceuticals and Everest Medicines holds exclusive rights for development, production, and commercialization in Greater China and South Korea. The medication has been approved in various regions, including Macau, Singapore, the United States, and the European Union. Everest Medicines has also submitted a new drug application for VELSIPITY® in Hong Kong, China.

VELSIPITY® is the first advanced oral therapy approved for use in patients 16 years and older in the EU. Clinical trials have shown positive results in both induction and maintenance treatment periods, with a good safety profile and convenient once-daily dosing. The medication provides a solid scientific basis for its wide application in clinical practice.

About VELSIPITY® (etrasimod)

VELSIPITY® is a once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in several countries for VELSIPITY® in ulcerative colitis.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing transformative pharmaceutical products and vaccines to address critical unmet medical needs in Asian markets. The company’s management team has extensive expertise in various aspects of the pharmaceutical industry. Everest Medicines aims to provide innovative solutions for renal diseases, infectious diseases, and autoimmune disorders. For more information, please visit www.everestmedicines.com.

Forward-Looking Statements:

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

Source: Everest Medicines
via PRNewswire